Literature DB >> 21120496

Macrophage activation syndrome resistant to medical therapy in a patient with systemic lupus erythematosus and its remission with splenectomy.

Ji Min Kim1, Seung Ki Kwok, Ji Hyeon Ju, Kyung Su Park, Gyeong Sin Park, Ho Youn Kim, Sung Hwan Park.   

Abstract

Macrophage activation syndrome (MAS) is a rare, but potentially life-threatening complication of systemic lupus erythematosus (SLE). A bone marrow biopsy often provides pathologic evidence of MAS, and MAS usually responds to corticosteroids alone or with the addition of cyclosporine A. We describe a case of MAS developing in a pregnant patient with SLE, who presented with fever and pancytopenia. Extensive investigations could not find the evidence of infection. Although intensive medical treatment was performed with a suspicion of MAS based on clinical grounds, no response was observed and bone marrow biopsy showed no evidence of hemophagocytosis. Positron emission tomography/computed tomography (PET/CT) suggested the possible cause of fever was in the spleen where fluorodeoxyglucose uptake was markedly increased. After splenectomy, the patient was improved and numerous hemophagocytic macrophages were proved in the splenic tissue. With this unique case, we would like to emphasize that bone marrow biopsy cannot always be relied on in making a diagnosis of MAS and PET/CT can provide helpful information in the diagnosis of MAS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21120496     DOI: 10.1007/s00296-010-1654-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  13 in total

Review 1.  Macrophage activation syndrome--what's in a name!

Authors:  Athimalaipet V Ramanan; Rayfel Schneider
Journal:  J Rheumatol       Date:  2003-12       Impact factor: 4.666

2.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

3.  Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders.

Authors:  S Sawhney; P Woo; K J Murray
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

Review 4.  Clinical significance of diffusely increased splenic uptake on FDG-PET.

Authors:  Yiyan Liu
Journal:  Nucl Med Commun       Date:  2009-10       Impact factor: 1.690

5.  Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients.

Authors:  J L Stéphan; I Koné-Paut; C Galambrun; R Mouy; B Bader-Meunier; A M Prieur
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

6.  Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases.

Authors:  S Fukaya; S Yasuda; T Hashimoto; K Oku; H Kataoka; T Horita; T Atsumi; T Koike
Journal:  Rheumatology (Oxford)       Date:  2008-09-09       Impact factor: 7.580

7.  Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection.

Authors:  M Hadchouel; A M Prieur; C Griscelli
Journal:  J Pediatr       Date:  1985-04       Impact factor: 4.406

8.  Reactive hemophagocytic syndrome--a clinicopathologic study of 40 patients in an Oriental population.

Authors:  K F Wong; J K Chan
Journal:  Am J Med       Date:  1992-08       Impact factor: 4.965

9.  The acute lupus hemophagocytic syndrome.

Authors:  K F Wong; P K Hui; J K Chan; Y W Chan; S Y Ha
Journal:  Ann Intern Med       Date:  1991-03-01       Impact factor: 25.391

Review 10.  Familial and acquired hemophagocytic lymphohistiocytosis.

Authors:  Gritta E Janka
Journal:  Eur J Pediatr       Date:  2006-12-07       Impact factor: 3.860

View more
  8 in total

1.  Association of Macrophage Activating Syndrome with Castleman's Syndrome in Systemic Lupus Erythematosus.

Authors:  Shamsa Shariatpanahi; Shahryar Pourfarzam; Mohammadhosein Gheini
Journal:  Iran J Pathol       Date:  2016

2.  Deficiency in IRAK4 activity attenuates manifestations of murine Lupus.

Authors:  Michael Murphy; Goutham Pattabiraman; Tissa T Manavalan; Andrei E Medvedev
Journal:  Eur J Immunol       Date:  2017-03-31       Impact factor: 5.532

Review 3.  Haemophagocytic lymphohistiocytosis in pregnancy.

Authors:  Harold Wilson-Morkeh; Charlotte Frise; Taryn Youngstein
Journal:  Obstet Med       Date:  2021-09-26

Review 4.  Refractory hemophagocytic syndrome in systemic lupus erythematosus successfully treated with intermittent intravenous cyclophosphamide: three case reports and literature review.

Authors:  Yo Ueda; Hiroyuki Yamashita; Yuko Takahashi; Hiroshi Kaneko; Toshikazu Kano; Akio Mimori
Journal:  Clin Rheumatol       Date:  2013-12-18       Impact factor: 2.980

5.  Discoid Lupus Erythematosus Complicated with Pregnancy-induced Hemophagocytic Syndrome.

Authors:  Hideto Takada; Naoki Kimura; Yoko Yoshihashi-Nakazato; Kimito Kawahata; Hitoshi Kohsaka
Journal:  Intern Med       Date:  2017-06-15       Impact factor: 1.271

6.  Hemophagocytic Lymphohistiocytosis in Pregnancy: A Case Series and Review of the Current Literature.

Authors:  Jessica Parrott; Alexander Shilling; Heather J Male; Marium Holland; Cecily A Clark-Ganheart
Journal:  Case Rep Obstet Gynecol       Date:  2019-02-12

Review 7.  Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review.

Authors:  Soamarat Vilaiyuk; Nongnuch Sirachainan; Suthep Wanitkun; Kwanchai Pirojsakul; Jarin Vaewpanich
Journal:  Clin Rheumatol       Date:  2013-03-13       Impact factor: 3.650

8.  Macrophage Activation Syndrome (MAS) in a Recently Released Prisoner with Systemic Lupus Erythematosus (SLE).

Authors:  Robert Szulawski; Peter J Kourlas; Marc Antonchak
Journal:  Am J Case Rep       Date:  2018-06-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.